Advertisement
Canada markets open in 3 hours 6 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7260
    -0.0004 (-0.05%)
     

  • CRUDE OIL

    82.39
    -0.34 (-0.41%)
     

  • Bitcoin CAD

    89,283.26
    +4,477.50 (+5.28%)
     

  • CMC Crypto 200

    1,337.65
    +25.03 (+1.95%)
     

  • GOLD FUTURES

    2,396.90
    -1.10 (-0.05%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • NASDAQ futures

    17,445.50
    -101.75 (-0.58%)
     

  • VOLATILITY

    19.04
    +1.04 (+5.78%)
     

  • FTSE

    7,838.63
    -38.42 (-0.49%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6815
    -0.0006 (-0.09%)
     

Nexstim Receives an NBS System Order from a Hospital in the Middle East

Nexstim Oyj
·2 min read

Press release, Helsinki, 27 October 2021 at 9 AM (EEST)

Nexstim Receives an NBS System Order from a Hospital in the Middle East

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received an NBS system order from a hospital in the Middle East.

Nexstim’s NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. This specific NBS system also includes the software of an NBT® system, allowing the system to also be used for therapeutic treatments.

Mikko Karvinen, CEO of Nexstim commented: “Even though our presence is the strongest in the North American and European markets, operating in markets such as the Middle East is important for us. We are happy to see internationally occurring interest in our systems that enable both diagnostic and therapeutic applications. At Nexstim, we work hard to bring our technology available for as many people as possible; offering solutions to the global challenge of how to effectively diagnose and treat brain diseases and disorders.

ADVERTISEMENT

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO
+358 50 326 4101
mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition, Nexstim is commercializing its SmartFocus® based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information please visit www.nexstim.com

Attachment